Americans need affordable access to medicines, but upper payment limits (UPLs) set by prescription drug affordability boards and Medicare Maximum Fair Prices (MFPs) are not viable solutions. In our complex drug supply chain, these price caps could bankrupt pharmacies and reduce patient access.

Read our handout for other strategies, and save it to share with others.